REIMAGINING THE POSSIBLE

2025 ANNUAL REPORT

CCRM

Commercializing
Living Therapies

CCRM is a Canadian, public-private partnership supporting the commercialization of cell and gene therapies with strategic funding, dedicated infrastructure and specialized business and scientific expertise. By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative CDMO services, scaling emerging companies by catalyzing investment, and training the workforce, CCRM is accelerating the translation of promising technologies, processes and therapies into life-changing health outcomes for patients.

CONTENTS

Our Mission

CCRM's mission is to generate sustainable health and economic benefits through global collaboration in cell and gene therapy, and regenerative medicine.

Our Vision

To be the preferred partner for the best people, technologies, clinical trials, companies and investments in regenerative medicine.

To be the premier global enabler of clinically-tested, revolutionary new medical therapies and foundational technologies.

CCRM is revolutionizing health care by solving the big problems in regenerative medicine.

Board of Directors

CHAIR

Michael Nobrega
Corporate Director
(Toronto)

BOARD

Emmanuel Abate
Cytiva (Paris)

Dozie Amuzie
Johnson & Johnson (Springhouse)

Reni Benjamin
Citizens Bank (New York)

Abi Coman-Walker
Nicola Wealth (Vancouver)

Leah Cowan
University of Toronto (Toronto)

Claudia Krywiak
OCI (Toronto)

Michael May
CCRM (Toronto)

Christopher Paige
UHN (Toronto)

Joan Sheehan
STEMCELL Technologies (Vancouver)

Peter Zandstra
CCRM (Vancouver)

Claudia Zylberberg
Kosten Digital (Boca Raton)

Committed to Progress, Driven by Purpose

The past year has tested our resilience, sharpened our focus, and strengthened our resolve. While we faced significant external pressures, we also advanced bold initiatives that position CCRM for its next phase of impact. Looking forward, we remain deeply committed to driving innovation that reshapes health care for patients worldwide.

In December, CCRM announced an exciting new collaboration with IonQ, a global leader in quantum computing. This partnership positions us at the forefront of innovation where advanced therapies, including cell and gene therapies, intersect with quantum technologies. IonQ has made a significant investment to accelerate joint initiatives across CCRM's expanding global network. The partnership also includes CCRM Nordic, our hub in Sweden, where IonQ already collaborates with AstraZeneca, and new projects are planned for 2026.

For some time now, CCRM has been laying the groundwork for an international network of hubs dedicated to accelerating regenerative medicine innovation. With hubs launched in Australia and Sweden in 2022 and 2023, respectively, our new collaboration with IonQ underscores CCRM's commitment to leveraging frontier technologies, such as cell differentiation and gene editing on the advanced therapy side, or artificial intelligence (AI) and quantum computing on the deep tech side, to transform medical innovation worldwide.

Quantum computing brings unprecedented computational power that can address long-standing challenges in biomanufacturing, analytics, logistics and supply chain, as well as in therapeutic development. By combining CCRM's leadership in next-generation therapeutics with IonQ's cutting-edge quantum capabilities, we aim to unlock new solutions that traditional methods cannot reach.

Our collaboration will focus on four priorities:

- **Identifying high-impact quantum use cases** in advanced therapy development.
- **Accelerating innovation in advanced biomanufacturing** to reduce the cost of therapies and expand patient access.
- **Integrating data, automation, AI and quantum computing** to transform therapy development, manufacturing and delivery.
- **Establishing the DeepTech Bio Lab™**, an industry–academic consortium dedicated to testing platforms and models at the convergence of deep tech and life sciences. This new workspace is inspired by the Centre for Advanced Therapeutic Cell Technologies, a centre of excellence in biomanufacturing that we launched in 2016 in partnership with Cytiva and funding from the Government of Canada.

This year, CCRM celebrates its

15th

anniversary

OmniaBio Inc., our contract development and manufacturing organization (CDMO) subsidiary, specializing in Good Manufacturing Practices (GMP) manufacturing of cells and viral vectors, will help ensure that biomanufacturing innovations emerging from this collaboration translate into real-world impact and industry adoption.

We have already been using AI in our Venture by Design program that employs purpose-built platforms to quickly and effectively evaluate a wide range of company concepts and "future-proof" their development. Since establishing Venture by Design, we have had success in identifying business opportunities and then devising novel technology solutions that address unmet needs in health care. We currently have five companies in development through Venture by Design.

In September, I accepted the role of interim CEO of OmniaBio following the departure of Mitchel Sivilotti. While the Board of Directors conducts its search for a permanent CEO, I remain committed to strengthening OmniaBio's capabilities as Canada's largest CDMO for cell and gene therapies, supporting innovators across North America and beyond. I am fortunate to work alongside a very skilled and dedicated team driving this vision forward.

I also want to recognize the exceptional team at CCRM. With many of them surpassing five and even 10 years of employment with the company, I am truly grateful for their loyalty and commitment to CCRM's purpose: revolutionizing health care by solving the big problems in regenerative medicine.

In 2026, CCRM will celebrate its 15th anniversary. It has gone by remarkably quickly, though not without periods of difficulty as we navigated day-to-day operational challenges and external forces beyond our control. While the pandemic brought attention and investment to the life sciences sector, its after-effects, combined with tariff pressures and broader economic headwinds, made the past year one of our hardest. Yet with 2025 behind us, multiple exciting venture concepts in development, and new strategic directions ahead, I am optimistic. We will continue building on strong relationships, forging new ones, and "reimagining the possible" together.

I invite you to join us on this journey.

Michael H. May
President and CEO

Worth Noting in 2025

CCRM leaders receive prestigious awards

Congratulations to CCRM's Michael May, President and CEO, who was awarded the University of Toronto Engineering Distinguished Alumni Award, the Engineering Alumni Network's highest honour. Peter Zandstra, the organization's Chief Scientific Officer, received the 2025 Killam Prize, which recognizes outstanding career achievements in research. These awards highlight the professional accomplishments of both individuals within their field.

Celebrating outstanding scientific leadership

Congratulations to Janet Rossant, President of the Gairdner Foundation, on receiving Life Sciences Ontario's Lifetime Achievement Award, and to Gordon Keller, Director of the McEwen Stem Cell Institute, for earning the International Society for Stem Cell Research's Achievement Award. These honours recognize their groundbreaking contributions to stem cell science and regenerative medicine. CCRM is proud to have both leaders as valued scientific advisors, whose vision, mentorship, and pioneering research continue to shape the field and inspire the next generation.

New partnership will accelerate Ontario's RM ecosystem

In June, the Ontario Centre of Innovation and CCRM announced they would be partnering to accelerate Ontario's regenerative medicine (RM) ecosystem, including cell and gene therapy. The collaboration will escalate progress in biomanufacturing, talent development and industry growth, to strengthen the province's position as a global leader in the sector. The announcement included supporting the growth of CCRM's CDMO subsidiary, OmniaBio Inc., as it advances a blueprint for biomanufacturing of the future through AI and automation.

Grand Prize Winner: Tatiana Koike and Jessica Poletto Bonetto





More entries in this year's contest. Photos (l to r): Beatriz Elena Lucumi Villegas, Lisa Bianchin, and Amna Nouman.

2025 Cells I See Art Contest – *Grand Prize Winner*

This year's Grand Prize winner was "The Bloom of Neuromuscular Transmission" by Tatiana Koike and Jessica Poletto Bonetto, CHU Sainte-Justine. This award is always chosen by attendees at the Till & McCulloch Meetings, an annual gathering of the Canadian stem cell community, hosted by the Stem Cell Network.

CCRM receives award for excellence in science communications

The Royal Canadian Institute for Science has awarded the William Edmond Logan Award to CCRM "for outstanding contributions to the public understanding of science by a Canadian organization." The award recognizes CCRM's podcast – *Commercializing Living Therapies with CCRM* – and its blog – *Signals*. Links to both can be found on CCRM's website. Past winners include CBC's Quirks & Quarks, Sanofi Pasteur Canada, IBM Canada and Celestica.

Happy birthday Medicine by Design!

Medicine by Design marked its 10th anniversary, celebrating a decade of strategic investment in regenerative medicine, including $77 million supporting 180 projects and contributions to 55 startups that have attracted $2.4 billion. As it enters its next decade, a new strategic alliance with CCRM positions it as CCRM's academic research division, strengthening national collaboration and accelerating the translation of high-risk, high-reward regenerative medicine discoveries into impactful therapies.

BY THE NUMBERS

12 Months

OmniaBio's Hamilton facility grand opening to Drug Establishment License approval

100% Border Performance

21 cord blood units successfully delivered

500 vials in 15 minutes

Two newly qualified GMP fill-finish systems now deliver high-speed, high-standard processing for iPSC drug substance and drug product

3831 Downloads

Commercializing Living Therapies with CCRM podcast

50,000+

Combined followers on LinkedIn for CCRM and OmniaBio



2025 Cells I See Art Contest
People's Choice Award Winner

Congratulations to Iram Fatima Siddiqui, McGill University, for once again (see our 2023 annual report) receiving the Cells I See People's Choice Award for "Stem Cell Web" and for receiving a record number of votes. The People's Choice is awarded to the entry with the highest number of likes on Facebook.

Manufacturing Momentum: OmniaBio's Strategic Progress



Achievement Despite Headwinds

In a year marked by industry challenges, OmniaBio Inc. continued to demonstrate resilience, strategic focus, and operational success as Canada's largest contract development and manufacturing organization (CDMO) dedicated to cell and gene therapies. Amidst a difficult landscape, the company achieved several critical milestones that reinforce its long-term vision and commitment to transformative medicine.

Renewed Focus

Following the departure of founding CEO Mitchel Sivilotti, OmniaBio welcomed Michael May as Interim CEO in September. As President and CEO of CCRM, Dr. May brings deep sector expertise and a renewed emphasis on operational excellence.

Strategic Collaboration with BrainChild Bio

In October, OmniaBio announced a manufacturing relationship with BrainChild Bio, a clinical-stage biotech focused on pediatric brain cancers. The collaboration will support Good Manufacturing Practices (GMP) manufacturing of BCB-276, an autologous CAR T therapy targeting diffuse intrinsic pontine glioma (DIPG)—a rare and aggressive brain tumour affecting children. This alliance not only underscores OmniaBio's technical capabilities but also its commitment to patient-centred innovation and scalable manufacturing solutions.

Rich Getto, the program lead at BrainChild Bio, was interviewed on *The Cell Tower* – the OmniaBio vodcast – to discuss why the BrainChild team chose OmniaBio. In the interview, Rich emphasized BrainChild Bio's mission to transform treatment for central nervous system tumours, which remain among the most challenging and devastating cancers. He noted that the partnership with OmniaBio provides a strong foundation to refine processes and deliver therapies for pediatric patients. This collaboration marks an important step toward "changing the game" in how these tumours are treated, with the ultimate goal of extending time and hope for affected families. You can watch the full episode here or read the press release.

Accelerated Regulatory Achievement

OmniaBio secured its Drug Establishment License (DEL) from Health Canada in record time, just over one year after the facility's opening ceremony in Hamilton, Ontario (read about it here), a testament to the company's operational rigour and regulatory readiness. This achievement enables preclinical to commercial manufacturing of advanced therapies, and positions OmniaBio as a trusted partner for global biopharma clients seeking compliant, scalable production in Canada.

Momentum Through Key Milestones

These milestones reflect a forward-looking strategy rooted in innovation, collaboration and execution. With a state-of-the-art facility a short drive from the U.S. border, and a growing portfolio of international partnerships, OmniaBio remains committed to bringing maturity to cell and gene therapy manufacturing, serving tomorrow's patients today.

Building a Stronger Workplace Culture

In a competitive market like ours, talent retention is paramount. Over the years, CCRM has been building its team and developing programs to provide an employee-centric culture. Here are some of our initiatives.





CEO Culture Council

The CEO Culture Council continues to make meaningful changes in our organization by addressing areas for improvement and launching new programs to promote organizational culture through volunteerism, mentorship and diversity initiatives.

Menopause Works Here

The Menopause Works Here campaign, spearheaded by the Menopause Foundation of Canada, is a Canadian initiative that encourages workplaces to support employees experiencing menopause. It aims to create menopause-inclusive workplaces that address the needs of women during this stage of life. It is estimated that the unmanaged symptoms of menopause cost the economy $3.5 billion per year.

CCRM joined the Menopause Works Here campaign in early 2025 to foster a menopause-inclusive workplace, which aligns with the demographics of our staff. The CCRM team is almost 60 per cent female. Of the female population, over 40 per cent are over 40. Out of our total workforce population, women over 40 make up a quarter. So far, we have shared relevant resources and events, identified health benefits employees can use, and provided tools for managers to support their colleagues.

Menopause Works Here™

Menopause Foundation of Canada

Volunteer Committee

The Volunteer Committee continued to build on successful existing partnerships – with Visions of Science and Canadian Blood Services – and introduced a new one. On a chilly May weekend, CCRM volunteers supported University Health Network in its inaugural fundraising walk, which raised over $1.43 million.

CCRM Connect

We launched CCRM Connect to create a vibrant and engaged alumni network and have since expanded it to include our Board of Directors, the CCRM hubs and the CCRM Group of Companies. This year, our **Mentorship Program** invited a select group of alumni and Board members to be mentors when the new cohort meets in 2026. We anticipate that this will be a success and a regular addition to the program, moving forward.

Croissants & Conversations

Launched at the end of 2024, Croissants & Conversations has been bringing staff together in an enjoyable and relaxed environment for food and networking. The casual weekly event encourages members from different teams to socialize and have fun together. The gathering also celebrates holidays and cultural events that occur throughout the year and fosters a sense of belonging at work.

The CCRM Group of Companies

The CCRM Group of Companies—comprising OmniaBio Inc., CCRM Enterprises Inc., LineaBio Inc., The CCRM Foundation and the Canadian Advanced Therapies Training Institute (CATTI)—continues to strengthen Canada's position as a global leader in regenerative medicine and advanced therapies. Together, these organizations form an integrated innovation ecosystem that spans commercialization, manufacturing, talent development and investment.

In 2025, the Group advanced its collective mission to accelerate the development of life-changing therapies by fostering industry partnerships, enabling cutting-edge biomanufacturing, supporting world-class research, and expanding training capacity to meet the growing needs of the advanced therapies workforce. To learn about OmniaBio's 2025 achievements, visit pages 8-9. To read about CATTI's progress, see page 15.

Below are highlights from CCRM Enterprises, LineaBio and The CCRM Foundation.

CCRM Enterprises' portfolio companies made significant announcements in 2025, which you can read about on pages 18 and 19. A highlight for the team was hosting the eighth edition of SuperPitch, in partnership with CCRM Australia and CCRM Nordic. This year, SuperPitch invited six early-stage companies, from the host countries, to present their technologies to life sciences venture capital firms and investors for valuable feedback.

Late in 2025, **LineaBio** announced the completion of whole genome sequencing of its first off-the-shelf Good Manufacturing Practices induced pluripotent stem cell line, Linea 1, using sequencing and bioinformatics services provided by STEMCELL Technologies, Inc. of Vancouver.

Building on Canada's legacy of research and innovation in regenerative medicine, **The CCRM Foundation** envisions a future where cell and gene medicines relieve the burden of living with chronic disease for Canadian families. Its mission is to address key gaps and challenges in bringing cell and gene medicines to patients. **The CCRM Foundation** has been developing its inaugural fundraising campaign to secure funding from philanthropic, government and private sector partners. An inaugural donor is expected to kick-start our pipeline of activities and advance three refined strategic priorities:

1. Advance academic-led innovations towards clinical translation and commercialization;

2. Develop early proof-of-concept data in support of novel venture ideation; and,

3. Foster global talent development (e.g., Summer by Design) and engage the community through convergent working groups.

The CCRM Foundation is planning for a convergent working group to take place in early 2026, focused on next-generation cell and gene immunotherapies. The workshop will identify key issues, bottlenecks and opportunities to advance Canada's leadership in next-generation cell and gene therapies.

Advancing CCRM's Global Mission Through its International Hubs

CCRM Nordic

CCRM Nordic continues to mature as a vibrant hub for advanced therapy medicinal product (ATMP) development in the Nordic region and made important progress in 2025. The team has grown to nearly 30 employees, reflecting its expanding capacity to support advanced therapy innovation.

Over the past year, CCRM Nordic has executed several projects across cell and gene therapy. A major milestone was its first venture investment: it became a shareholder in Precision BioAnalytics AB, partnering to accelerate molecular analysis in ATMP development.

The immune-oncology workflows are now fully operational, generating strong data and validating the analytical platforms. CCRM Nordic has also established its first pluripotent stem cell workflow and laid out a clear strategy for future viral therapy work.

On the infrastructure side, construction of the new facility in GoCo Health Innovation City is proceeding on schedule, with handover of the building expected mid-2026.

CCRM Nordic remains aligned with its long-term mission to de-risk and accelerate translation of advanced therapies — enabling academic and industry innovators across Europe to move from concept to clinic.

CCRM Australia

In 2025, CCRM Australia further strengthened its role as a catalyst for regenerative medicine commercialization across the nation. It deepened engagement with industry, academia and government through a growing national partner network, leveraging global expertise from the CCRM consortium to support Australian innovators.

A major milestone this year was CCRM Australia's pivotal role in the successful SMART CRC (Solutions for Manufacturing Advanced Regenerative Therapies) application, in partnership with the University of Queensland. This initiative secured AU$238 million in coordinated investment and unites 63 partners across government, industry, small and medium-sized enterprises, universities, research institutes and medical providers. The SMART CRC will significantly enhance Australia's capability to develop, manufacture and commercialize advanced regenerative therapies, creating new pathways for research translation and industry collaboration.

CCRM Australia also expanded international and domestic partnerships. A strategic collaboration with SMS Biotech Inc. of San Diego, California, provides advisory support to its Australian subsidiary, SMSbiotech Australia Pty Ltd., which has a candidate in a Phase I clinical trial. CCRM Australia is helping to develop and implement commercialization strategies to support the company's growth and global footprint.

Further, collaboration with the RNA Institute at the University of New South Wales is enabling the advancement of gene therapy-related technologies, reinforcing Australia's position in cutting-edge cell and gene therapy research.

Looking ahead, CCRM Australia continues to drive the Advanced Cell Therapy Manufacturing Initiative (ACTMI), a process development facility at the University of Queensland that leverages CCRM and OmniaBio's bioprocessing expertise. ACTMI is expected to be operational in 2026, further cementing Australia's national capability in cell and gene therapy manufacturing.

Overall, 2025 has been marked by strengthened partnerships, innovation in process development, and meaningful contributions to progress Australia's cell and gene therapy ecosystem.

CCRM Australia and government representatives visit OmniaBio, June 2025

The CCRM Australia bid team for the SMART CRC application

Meetings with organizations from 16 different international countries

Meetings with 6 Australian states and territories



A total of 376 meetings – averaging 34 per month

CATTI: Expanding Biomanufacturing Training Across Canada

Launched in 2021 as a partnership between Montreal-based CellCAN and CCRM, 2025 was a pivotal year for the Canadian Advanced Therapies Training Institute (CATTI). Building on its mission to develop a Good Manufacturing Practices (GMP)-trained workforce in Canada, CATTI reached several key milestones. With new funding from Palette Skills, in partnership with OBIO, CATTI expanded its delivery of biomanufacturing training programs across Canada. Palette Skills works with industry and training partners to develop and fund upskilling programs and is funded by the Government of Canada. OBIO is a not-for-profit, membership-based organization offering programming and infrastructure to support early-stage and venture-backed companies in life sciences and health tech.

Over the past year, CATTI has trained more than 200 individuals through hands-on and online programs. Training was extended at new sites, including STEMCELL Technologies in Vancouver, MATREC at McGill University in Montreal, and Carleton University in Ottawa. Additionally, CATTI delivered customized private training for the University of Montreal Health Centre ("CHUM") at their facility, addressing the institution's specific biomanufacturing training needs.

This year saw the launch of a new bootcamp focused on Quality Control Microbiology, further broadening CATTI's practical training offerings. A new online in-depth course on Quality Control Analytics, in partnership with OBIO, was also released at the end of 2025. Through these programs, participants strengthened their skills in aseptic processing, clean room practices, and quality control, supporting the growing demand for a skilled workforce in advanced therapies manufacturing.

CATTI is also deepening its collaborations with CCRM Australia and CCRM Nordic.

> ***The Biomanufacturing for Advanced Therapies program was an outstanding hands-on training experience where I developed practical skills in cell culture and aseptic technique within a GMP framework. The blend of theory and practice has enhanced my expeartise and provided me with a strong competitive edge in the biotech field."***
>
> **– Andres Dumas, Biochemistry Scientist, SteriLabs Canada**

CCRM staff and Visions of Science students at CCRM, March 2025

Participants of Summer by Design, June 2025

Summer by Design

Now in its sixth year, Summer by Design, led by Medicine by Design (MbD), was an eight-day intensive program for graduate students from Canadian and international universities interested in learning about translating and commercializing regenerative medicine discoveries. Sessions were led by employees at CCRM, OmniaBio Inc., CATTI, Rotman School of Management at the University of Toronto (U of T), and Talk Boutique for public speaking training. Program participants represented 14 institutions spanning four continents and work in cell therapy, gene editing, stem cells, immunotherapy, organoids, tissue engineering, organ-on-a-chip, biomaterials, bioinformatics and drug delivery. Since its inception in 2017, Summer by Design has had 200 program alumni from 45 global institutions and 15 countries.

Building a Biotech Venture

BoutIQ Solutions Inc. was named the 2025 Building a Biotech Venture Grand Prize winner by MbD for its AI/machine learning-powered platform to optimize cell culture media development for regenerative medicine, biotechnology and cellular agriculture. The venture is led by Alice Feng, Heta Lad and Doris Adao from the labs of Julie Audet and Craig Simmons at U of T. The team was awarded $25,000 in research funding, provided by PRiME Next-Generation Precision Medicine and MbD. Now in its fifth year, 12 MbD investigator and trainee teams have participated in the six-month training program designed to support the next generation of entrepreneurs as they take the first steps toward building their technology into a product or venture.

CCRM hosts Visions of Science students during March break

Participants of Visions of Science's STEM Academy visited CCRM to participate in DNA-focused education and experiments, led by our employees. Based in Toronto, Visions of Science takes a proactive approach by engaging youth at critical stages of development and facilitating year-round science, technology, engineering and math (STEM) learning opportunities to strengthen support networks and ensure equitable STEM education, along with academic and career pathways. CCRM staff led the students in activities, which involved extracting DNA and solving a "genetic mystery." This event was part of a partnership between The CCRM Foundation and Visions of Science, announced in 2023.

Gene Therapy Canada networking reception hosted at CCRM

In April, Gene Therapy Canada, a not-for-profit group that connects and supports professionals working to advance gene therapies in Canada, hosted its inaugural networking event at CCRM, sponsored by AspireBio Consulting. Gene Therapy Canada's members and partners are researching, developing and manufacturing gene therapy products in Canada for the benefit of patients.

Building the Next Phase of Growth

This past year marked a significant milestone for Medicine by Design (MbD) as it moved on from its home at the University of Toronto (U of T). Building on a longstanding partnership with CCRM and the strategic alliance announced in December 2023, MbD has become the academic research division of CCRM. This closer integration with CCRM will sustain MbD into its next phase of growth, building upon the respective strengths of both groups: bridging high-risk, high-reward research to industry expertise, company creation, biomanufacturing infrastructure and the clinic.

In February, Allison Brown joined CCRM as Senior Vice President, Academic Engagement & Philanthropy. Dr. Brown has served as the Executive Director of MbD since 2019. In its new capacity, MbD will maintain strong engagement with its lead academic partner U of T, and the broader Toronto Academic Health Sciences Network, while also building strategic partnerships across Canadian and global academic institutions.

The Convergent Working Groups

To integrate investigators from disciplines and experiences that were new to the MbD community, it launched the Convergent Working Groups funding call in 2022. The second phase, in 2025, supported seven teams in addressing unmet critical needs in their fields of expertise. Examples included: bridging the regenerative medicine gap in African, Caribbean and Black communities; establishing Ontario as a rare disease gene therapy hub; designing clinical trials for premature infants with life-threatening conditions; and, exploring the role of artificial intelligence in transplant medicine.

Building trust with patients and the broader public who support health and medical research requires continuous engagement with the public and was an important focus of the Convergent Working Groups.

MbD participated in two Summits in 2025, with Indigenous communities falling under the auspices of the "7-Directions Summit on Regenerative Medicine and Brain-Heart Health:" one on Sturgeon Lake First Nation in Saskatchewan and one in Edmonton, Alberta. Both Summits were led by Alexandra and Malcolm King and supported by Pewaseskwan team members. The Summits brought together Knowledge Holders, youth, health leaders and individuals with lived and living experience of organ donation and transplantation to collaboratively envision a path forward for equitable inclusion in regenerative medicine therapies and to identify community priorities.[i] One outcome arising from the Summits was to adopt "regenerative healing" as a more welcoming and humbler framework on which to launch the conversation around advanced therapies.

MEDICINE by DESIGN

- Medicine by Design (MbD) launched in 2016 with $114 million from the Canada First Research Excellence Fund
- MbD has invested over $77 million into 180 research projects
- MbD investigators have secured over $975 million in additional research funds
- $40 million has come from industry partners
- The MbD community has launched 55 startups
- These companies have attracted $2.4 billion in investment

[i] Alexandra King, Taiwo Ametepee, Carrielynn Lund, Malcolm King, The 7-Directions Summit on Regenerative Medicine and Indigenous Peoples in Canada: Knowledge Holders' Gathering. Poster presented at Medicine by Design's Annual Symposium, Toronto, Ontario, December 2023.

Portfolio Company Highlights

Through CCRM Enterprises, CCRM provides tailored support to advance promising discoveries from lab to market, supporting the launch and development of 20 companies that have collectively raised over $1 billion. Despite the fact that 2025 was a challenging year for early-stage companies in life sciences, CCRM's portfolio companies continued to advance their development. Here are a few notable examples.

Feldan Therapeutics

Quebec City

Feldan Therapeutics announced two additional investments to its Series B in 2025 to support the progression of its lead candidate, FLD-103, a non-surgical treatment for basal cell carcinoma (BCC) currently in clinical trials, and to help accelerate the expansion of its pipeline. Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), focuses on identifying and investing in promising early-stage and growth-stage health care companies. Linearis Ventures pioneers and supports discoveries to prevent, detect and treat metabolic diseases.

Feldan also received non-dilutive funding to support the optimization of its proprietary intracellular delivery platform.

ExCellThera

Montreal

ExCellThera's Zemcelpro® (UM171 Cell Therapy) received European Commission conditional marketing authorization as the first and only cell therapy for blood cancer patients requiring allogeneic stem cell transplant, including those with leukemias and myelodysplastic syndromes, without access to suitable donor cells. ExCellThera's subsidiary Cordex Biologics is actively seeking strategic partnerships to accelerate the commercialization of Zemcelpro® in Europe and other markets.

CLICK THE BOXES TO GET TO THEIR WEBSITES!

Pluristyx

Seattle

Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, in July 2025, announced the successful close of its most recent round of funding led by BioLife Solutions and BroadOak Capital Partners. The newly raised capital will enable Pluristyx to expand commercial operations and build inventory with new clinical-grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ safety switch and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogrammed iPSCs. Pluristyx also announced, in November 2025, an award of a grant from Breakthrough T1D to further develop one of their keystone technologies, iACT and FailSafe for the treatment of Type 1 diabetes and the licensing of its iPSC lines by two therapeutics developers.

Aspect Biosystems

Vancouver

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, announced that it closed a US$115 million Series B financing round. The financing was led by Dimension with participation from investors including Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture. Proceeds from the Series B will enable Aspect to advance multiple bioprinted tissue therapeutics towards the clinic with a mission to deliver a new class of cellular medicines and functional cures for people living with serious metabolic and endocrine diseases.

This financing builds on Aspect's recent momentum, including a CA$200 million partnership with the governments of Canada and British Columbia, and a partnership with Novo Nordisk focused on diabetes and obesity.

Key Funders

NCE RCE

Federal Economic Development Agency for Southern Ontario

Agence fédérale de développement économique pour le Sud de l'Ontario

Ontario

Founding Institutional Members

University of Toronto

UHN Toronto General Toronto Western Princess Margaret Toronto Rehab Michener Institute

SickKids

The Ottawa Hospital Research Institute | L'Hôpital d'Ottawa Institut de recherche

Associate Institutions

LUMC

McMaster University

McGill

Monash University

Mount Sinai Hospital Sinai Health System Joseph & Wolf Lebovic Health Complex

The University of British Columbia

University of Calgary

Current and Former Portfolio Companies

Current

Apiary Therapeutics

Aspect biosystems

catti

endogena

ExcellThera

FELDAN Therapeutics

iVexSol

KisoJi

LineaBio

MEDIPHAGE

Mesentech

Morphocell technologies

OmniaBio

Persistence

pluristyx

Former

AVROBIO

Notch Therapeutics

Collaborative Partners

Industry Consortium

CCRM has established a consortium of more than 100 companies that represent key sectors of the regenerative medicine industry, including therapeutics, devices, reagents, and cells as tools. These companies range from multinational corporations, to small-medium enterprises, to emerging start-ups. They have utilized the translational platforms developed by CCRM to enable new opportunities and address real-life bottlenecks in their businesses.

CCRM would like to acknowledge the valuable relationships that have been fostered with these companies.

CCRM

Commercializing
Living Therapies

MaRS Centre, West Tower
661 University Avenue, Suite 1002
Toronto, ON, M5G 1M1
416-978-3751
www.ccrm.ca

@CCRM_ca

Follow us on LinkedIn

Like us on Facebook